Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHA:600381)
China · Delayed Price · Currency is CNY 3.020
-0.120 (-3.82%)
At close: Feb 13, 2026
SHA:600381 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 279.18 | 264.68 | 206.78 | 155.05 | 123.89 | 121.81 |
Other Revenue | 5.58 | 5.58 | 7.09 | 5.13 | 3.88 | 2.46 |
| 284.76 | 270.26 | 213.88 | 160.18 | 127.76 | 124.27 | |
Revenue Growth (YoY) | 13.36% | 26.36% | 33.52% | 25.37% | 2.81% | -46.84% |
Cost of Revenue | 198.17 | 203.49 | 86.27 | 138.5 | 147.78 | 118.82 |
Gross Profit | 86.59 | 66.77 | 127.61 | 21.68 | -20.02 | 5.45 |
Selling, General & Admin | 130.19 | 193.44 | 222.37 | 188.41 | 118.56 | 112.64 |
Research & Development | 12.91 | 14.56 | 11.64 | 11.38 | 9.54 | 12.3 |
Other Operating Expenses | 2.83 | 4.33 | 3.08 | 2.93 | 3.19 | 1.57 |
Operating Expenses | 157.35 | 223.16 | 246.81 | 229.43 | 189.87 | 145.16 |
Operating Income | -70.75 | -156.39 | -119.2 | -207.75 | -209.89 | -139.72 |
Interest Expense | -0.43 | -0.83 | -0.91 | -0.09 | -0.05 | - |
Interest & Investment Income | 1.2 | 1.13 | 1.36 | 0.5 | 0.17 | 0.11 |
Currency Exchange Gain (Loss) | 2.64 | 2.64 | -0.13 | -0.88 | 1.33 | -1.76 |
Other Non Operating Income (Expenses) | 3.89 | 1.38 | -0.31 | -0.52 | 5.79 | -6.91 |
EBT Excluding Unusual Items | -63.46 | -152.07 | -119.2 | -208.74 | -202.64 | -148.28 |
Gain (Loss) on Sale of Investments | -36.93 | -36.9 | -139.81 | -46.96 | -51.13 | -139.88 |
Gain (Loss) on Sale of Assets | 0.11 | -0.11 | 0 | 0.02 | -0.02 | -2.15 |
Asset Writedown | -8 | -7.9 | -0.03 | -40.68 | - | -25.43 |
Legal Settlements | - | - | - | - | -0.02 | -0.02 |
Other Unusual Items | -4.23 | -4.23 | -1.25 | 1.09 | 1.35 | 0.72 |
Pretax Income | -112.51 | -201.2 | -260.28 | -295.27 | -252.46 | -315.04 |
Income Tax Expense | -2.7 | -3.89 | 5.93 | -7.72 | -3.84 | 4.51 |
Earnings From Continuing Operations | -109.81 | -197.31 | -266.21 | -287.55 | -248.61 | -319.54 |
Minority Interest in Earnings | -1.34 | -1.46 | -1.65 | 0 | - | - |
Net Income | -111.15 | -198.77 | -267.87 | -287.55 | -248.61 | -319.54 |
Net Income to Common | -111.15 | -198.77 | -267.87 | -287.55 | -248.61 | -319.54 |
Shares Outstanding (Basic) | 572 | 585 | 582 | 587 | 592 | 592 |
Shares Outstanding (Diluted) | 572 | 585 | 582 | 587 | 592 | 592 |
Shares Change (YoY) | -1.50% | 0.39% | -0.77% | -0.86% | 0.03% | 1.89% |
EPS (Basic) | -0.19 | -0.34 | -0.46 | -0.49 | -0.42 | -0.54 |
EPS (Diluted) | -0.19 | -0.34 | -0.46 | -0.49 | -0.42 | -0.54 |
Free Cash Flow | -13.88 | 76.04 | 10.39 | -32.64 | -185.73 | -275.59 |
Free Cash Flow Per Share | -0.02 | 0.13 | 0.02 | -0.06 | -0.31 | -0.47 |
Gross Margin | 30.41% | 24.71% | 59.67% | 13.53% | -15.67% | 4.38% |
Operating Margin | -24.85% | -57.86% | -55.73% | -129.70% | -164.28% | -112.43% |
Profit Margin | -39.03% | -73.55% | -125.24% | -179.52% | -194.59% | -257.14% |
Free Cash Flow Margin | -4.87% | 28.14% | 4.86% | -20.38% | -145.37% | -221.77% |
EBITDA | -51.87 | -136.31 | -97.52 | -167.01 | -168.29 | -98.2 |
EBITDA Margin | -18.21% | -50.43% | -45.60% | -104.27% | -131.72% | -79.03% |
D&A For EBITDA | 18.89 | 20.08 | 21.68 | 40.74 | 41.59 | 41.51 |
EBIT | -70.75 | -156.39 | -119.2 | -207.75 | -209.89 | -139.72 |
EBIT Margin | -24.85% | -57.86% | -55.73% | -129.70% | -164.28% | -112.43% |
Revenue as Reported | 284.76 | 270.26 | 213.88 | 160.18 | 127.76 | 124.27 |
Advertising Expenses | - | 69.63 | 79.8 | - | 24.65 | 21.12 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.